Drug Trial Radar · NCT03263507
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Aug 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Aug 28, 2017
Primary completion
Oct 9, 2018
Study completion Oct 9, 2018
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Aug 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen administered subcutaneously to Healthy Volunteers
Conditions
- Healthy Volunteers
Interventions
PlaceboDrug
Saline .9%
DonidalorsenDrug
Donidalorsen administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events that are related to treatment with DonidalorsenTime frame: Up to 176 days
- Peak plasma Concentration (Cmax) of DonidalorsenTime frame: Up to 176 days
- Time to peak plasma Concentration (Tmax) of DonidalorsenTime frame: Up to 176 days
- Effects of Donidalorsen on plasma PKK concentrationTime frame: Up to 176 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ionis Investigative Site
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.